Highest-materiality recent filing
Turning Point Brands Q2 net sales up 22.6% to $142.9M; EPS falls to $0.18 from $0.79
Modern Oral net sales up 128% to $68.4M, now 48% of total net sales (26% in Q2 2025).
Turning Point Brands Q1 net sales up 17%, Modern Oral sales surge 133% to $52M; raises FY guidance
Total net sales $124.3M (+17% YoY); Modern Oral segment sales $52.0M (+133%), now 42% of total sales.
Turning Point Brands Q4 net sales up 29% to $121M; Modern Oral surges 266%
Q4 net sales $121.0M (+29.2% YoY); net income $8.2M (+239.8%); adjusted EBITDA $30.0M (+14.4%).
Turning Point Brands Q3: Modern Oral sales surge 628%, net sales up 31% to $119M; FY guidance raised
Consolidated net sales $119.0M (+31.2% YoY); Modern Oral sales $36.7M (+627.6%) now 30.8% of total.
TPB Q3 net sales $119M (+31.2% YoY); raises FY2025 Adjusted EBITDA guidance to $115-120M
Net sales $119.0M (+31.2% YoY); net income $21.1M (+70.3%); adjusted diluted EPS $1.27.
Turning Point Brands expands ATM equity program by $200M after exhausting prior $100M
Original ATM program of $100M nearly tapped with $99,999,137 gross proceeds sold.
Turning Point Brands Q2 net sales up 25% to $116.6M; Modern Oral surges 651%; raises guidance
Net sales $116.6M (+25.1% YoY); net income $14.5M (+11.3%); diluted EPS $0.79.
Turning Point Brands Q1 net sales up 28% to $106.4M; raises Modern Oral guidance to $80-95M
Net sales $106.4M (+28.1% YoY); diluted EPS $0.79 vs $0.63; Adj. diluted EPS $0.91 vs $0.80.
Turning Point Brands dismisses auditor RSM, appoints KPMG; cites material weakness in ITGC
RSM US LLP dismissed as independent auditor; KPMG LLP appointed for FY 2025 effective March 7, 2025.
TPB Q4 net sales +12.8% to $93.7M; FY24 adjusted EBITDA +12% to $104.5M
Q4 adjusted EBITDA $26.2M (+5.3%), adjusted diluted EPS $0.98 (vs $0.82).
Turning Point Brands issues $300M 7.625% Senior Secured Notes due 2032 to refinance 2026 Notes
$300M aggregate principal of 7.625% Senior Secured Notes due March 15, 2032 issued Feb 19, 2025.
Turning Point Brands prices $300M 7.625% senior secured notes due 2032
Offering of $300,000,000 aggregate principal amount of 7.625% Senior Secured Notes due March 15, 2032.
Preliminary Q4 2024 net sales estimated $93.1-$94.1M; full year $360-$361M.
TPB contributes CDS segment to GWO JV for 49% stake; option to buy remaining 51%
Contributed 100% of South Beach Brands (CDS segment) to GWO in exchange for 49% fully-diluted stake.
Turning Point Brands enters $100M ATM offering to fund FRE pouch expansion
Up to $100M of common stock may be sold via B. Riley Securities and Barclays Capital as sales agents.
Turning Point Brands Q3 beats; adjusted EBITDA up 11% to $27.2M; raises FY guidance
Q3 net sales $105.6M (+3.8% YoY); net income $12.4M (+14.3%); diluted EPS $0.68.
Turning Point Brands Q2 Adjusted EBITDA +7% to $27.0M; raises FY2024 guidance to $98-102M
Q2 2024 net sales up 2.8% to $108.5M; net income +31% to $13.0M; diluted EPS $0.68.
Turning Point Brands Q1 net income up 58%; adjusted EBITDA +22% to $25.3M
Net income $12.0M (+58.1% YoY); diluted EPS $0.63; adjusted diluted EPS $0.80 vs $0.62.
TPB appoints Andrew Flynn as CFO; Louie Reformina steps down effective March 8
Reformina steps down as CFO effective March 8, 2024 to pursue other opportunities; no dispute with company.
Turning Point Brands Reports Q4 2023 Adjusted EBITDA Up 7.5% to $24.8 Million
Q4 2023 net sales decreased 6.1% to $97.1 million; Zig-Zag and Stoker's combined grew 5.9%
TPB Q3 net sales down 5.6% to $101.7M; narrows 2023 adjusted EBITDA guidance to $92-95M
Adjusted EBITDA $24.4M (-0.4% YoY); diluted EPS $0.58, adjusted diluted EPS $0.76.
Turning Point Brands Q2 net sales up 2.6% to $105.6M; raises FY2023 EBITDA guidance to $90-95M
Net income rose 83% to $9.9M; adjusted diluted EPS $0.79 vs $0.70 a year ago.
Turning Point Brands Q1 net sales flat but net income down 30.9% to $7.6M
Net sales $101.0M (+0.1% YoY); gross profit fell 6.1% to $48.6M.
Turning Point Brands Q4 net loss $16.3M on $34.8M impairment; FY23 adj EBITDA guidance $88-94M
Q4 net sales $103.4M (-1.8% YoY); net loss $16.3M vs income $11.5M prior year due to $34.8M non-cash impairments.
Turning Point Brands Q3 net sales down 1.9% to $107.8M; lowers FY2022 EBITDA guidance
Net income fell 14.3% to $11.5M; diluted EPS $0.60 vs $0.65 a year ago; adjusted diluted EPS $0.72 (flat).
Yavor Efremov resigned as CEO and director effective Oct 15, 2022; no disagreement. Graham Purdy (previously COO) appointed CEO and board member.
Turning Point Brands Q2 net sales down 16.1% to $102.9M; cuts FY adj. EBITDA guidance
Net sales $102.9M (-16.1% YoY); net income $5.4M (-64.7%); diluted EPS $0.30 (adj. $0.70 vs $0.84).
Turning Point Brands Q1 net sales down 6.3% to $100.9M; adjusted EPS $0.71 vs $0.80
Zig-Zag segment net sales +11.4% to $45.7M; Stoker's +8.4% to $31.7M; NewGen -37.1% to $23.5M.
Turning Point Brands FY2021 net sales +10% to $445.5M, adj. EBITDA +19.8% to $108.1M
Q4 net sales flat at $105.3M, net income -20.3% to $11.5M, adj. EBITDA -7.6% to $23.8M; NewGen sales -22%.
Turning Point Brands appoints Yavor Efremov as CEO; Wexler retires after 18 years
Yavor Efremov appointed President and CEO, effective Jan 11, 2022, succeeding Larry Wexler who retires after 18 years.
Turning Point Brands Q3 sales +5.5% to $109.9M; cuts 2021 guidance; boosts buyback
Q3 net sales $109.9M (+5.5%), gross profit $54.3M (+12.3%), adjusted EBITDA $26.3M (+9.9%).
FDA rescinds Marketing Denial Order on TPB vapor products; products remain under review
On Oct 7, FDA rescinded its Sept 14 Marketing Denial Order for certain TPB vapor products, citing need for further review.
FDA issues Marketing Denial Order to Turning Point Brands for certain vapor products
FDA issued MDO on Sept 14, 2021, covering certain vapor products under PMTA.
Turning Point Brands raises FY2021 guidance after Q2 beat; Zig-Zag sales surge 72% YoY
Q2 net sales $122.6M (+16.8% YoY); net income $15.4M (+49.2%); adjusted EBITDA $30M (+31.7%).
the Board has nominated John Catsimatidis Jr. to stand for election as a director at the Company’s 2024 Annual Meeting.
On March 20, 2024, Arnold Zimmerman notified the Board of Directors (the “Board”) of Turning Point Brands, Inc. (“Turning Point” or the “Company”) of his decision to retire as a director after eleven years of distinguished service effective upon the expiration of his term at the 2024 Annual Meeting of Stockholders in May 2024.
Louie Reformina, Senior Vice President and Chief Financial Officer of the Company, would be stepping down from his position in order to pursue other opportunities, effective as of March 8, 2024.
The Board of Directors of the Company (the “Board”) has appointed Andrew Flynn to serve as Senior Vice President and Chief Financial Officer of the Company, with an anticipated start date of April 1, 2024, to take Mr. Reformina’s position.
she will not stand for reelection as a director of the Company at the 2023 Annual Meeting of Stockholders
the Board appointed Graham A. Purdy as President and Chief Executive Officer of the Company and as a member of the Board, effective as of October 16, 2022.
David Glazek, Chairman of the Board, will transition to the role of Executive Chair effective January 2023.
As part of this transition, Mr. Yavor Efremov has resigned as Chief Executive Officer and President and from the Board of Directors (the “ Board ”), effective as of October 15, 2022.
Mr. Wexler intends to retire as Chief Executive Officer effective January 10, 2022 after 18 years with the Company.
the Board has appointed Yavor Efremov to succeed Larry Wexler as President and Chief Executive Officer of the Company, effective as of January 11, 2022.
On July 9, 2021, the Board of Directors (the “Board”) of Turning Point Brands, Inc. (the “Company”), determined, upon the recommendation of its Nominating and ESG Committee to increase the size of the Board from eight to nine directors, and has appointed Yavor Efremov to fill the vacant board position, effective July 9, 2021.
Max materiality 0.85 · Median 0.75 · Most common event earnings